(NewsDirect)
Valeo Pharma CEO Steve Saviuk joinedProactive's Steve Darling to share news regarding thecompany's strong third-quarter performance.
The company has once again shattered itsown records, demonstrating remarkable growth in various key areas ofits business.
In 3Q 2023, thecompany achieved a milestone with record quarterly revenues reachingan impressive $14.1 million, a 132% increase when compared to the $6.1million generated in the same period of the previous year.
Notably, Valeo Pharma's two flagshipproducts for managing asthma, Enerzair and Atectura, were instrumentalin driving this growth, with a 234% increase in sales.
Adjusted gross profit soared to $5.1million, marking a 106% rise from the $2.4 million recorded in 3Q2022.
Enerzair and Atectura haveemerged as frontrunners in the Canadian asthma market, gainingprominence as essential therapies.
The company said it will focus on sales growth and improvedgross margins to put it on the path to profitability, with plans tooptimize costs further.
Valeo Pharma is optimistic about itsfuture prospects and anticipates sustained growth as it continues toserve a vital role in addressing healthcare needs.
ContactDetails
Proactive Investors
+1 347-449-0879
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.